When the Painkiller Becomes the Pain: A Clinician’s Guide to Opioid-Induced Hyperalgesia
Pain Spa · Clinician Guide
Opioid-Induced Hyperalgesia: When the Painkiller Becomes Part of the Pain
Recognition, mechanisms, prevention and management of OIH in perioperative and chronic pain practice
Key points
- OIH is a paradoxical, opioid-driven increase in pain sensitivity. Pain becomes more diffuse and gets worse, not better, as the dose rises.
- It reflects sensitisation of pronociceptive pathways centred on spinal NMDA receptors. Tolerance is a different process: desensitisation of antinociceptive pathways.
- There is no threshold dose or duration, but OIH clusters around high doses and remifentanil.
- Diagnosis is clinical and by exclusion. Improvement after dose reduction or rotation supports it.
- Prevention is opioid-sparing. Ketamine and dexmedetomidine are the best-supported adjuncts for both prevention and treatment.
What is opioid-induced hyperalgesia?
Opioid-induced hyperalgesia (OIH) is a paradoxical increase in pain sensitivity caused by opioid exposure: a diffuse, heightened response to noxious stimuli that is not explained by disease progression, and that worsens rather than improves as the dose goes up.1,2
OIH and tolerance both push opioid requirements upwards, but they are different processes. Tolerance is desensitisation of antinociceptive pathways, so the same dose does less. OIH is sensitisation of pronociceptive pathways, centred on spinal NMDA receptors, so the nervous system itself becomes more pain-sensitive.3
No dose or duration has to be reached first. OIH has been reported after brief intraoperative exposure and at low, high and maintenance doses.3,4 In practice, though, it clusters around high doses and potent short-acting phenylpiperidines, especially remifentanil.2,4,5 How common it is in clinical practice remains genuinely uncertain.
Distinguishing OIH from its look-alikes
| Condition | Core feature | Response to a higher dose |
|---|---|---|
| Tolerance1 | Less analgesia from the same dose; pain returns at its original intensity and location | Improves |
| OIH1,5 | Diffuse pain spreading beyond the original site, often with allodynia | Worsens |
| Withdrawal1 | Autonomic and gastrointestinal symptoms when the dose drops or is stopped | Improves (relieved by opioid) |
| Disease progression or new neuropathic pain5 | Pain follows the pathology | Variable; neuropathic pain responds poorly to opioids |
“When a patient tells me their pain has spread and become more sensitive even though their opioid dose keeps going up, I stop and ask whether the opioid itself has become part of the problem. More of the same is rarely the answer.”
— Dr Murli Krishna, Consultant in Pain Medicine, Pain Spa
Why does it happen? Mechanisms
- NMDA/glutamate activation: mu-opioid receptor activation on primary afferent terminals in the dorsal horn causes PKC-dependent phosphorylation and synaptic trafficking of presynaptic NMDA receptors, amplifying nociceptive input.6
- Spinal long-term potentiation: even brief opioid exposure strengthens input from TRPV1-expressing afferents onto excitatory spinal neurons. This depends on α2δ-1 and is abolished by gabapentin in animal models, which helps explain why intraoperative opioids can worsen postoperative pain.7
- Other contributors: increased spinal dynorphin, descending facilitation from the rostral ventromedial medulla, and neuroinflammation, including TLR4 signalling on nociceptors and astrocyte IL-1β release. β-arrestin-2 sensitisation of TRPV1 to heat also plays a part.5,8–10
- Chronic cellular adaptations: increased adenylate cyclase/PKA activity and enhanced NMDA function produce a hyperexcitable state.
How is it diagnosed?
There is no specific test; the diagnosis is clinical.4,5 Features that point towards OIH are:
- Spread: pain extends beyond the original site and changes in quality, with allodynia or hyperalgesia.1,5
- Paradoxical dose response: pain worsens when the dose is escalated.5
- Exclusion: disease progression, tolerance, withdrawal, new neuropathic pain and psychological contributors have been considered and ruled out.2,5
- Response to dose reduction: improvement with dose reduction or rotation supports OIH, whereas tolerance would be expected to respond to a dose increase.2
- Quantitative sensory testing (QST): can help objectify altered sensory processing. Hyperalgesia around a surgical wound may simply reflect surgical sensitisation; widespread hyperalgesia is more suggestive.5
The gut-specific form is narcotic bowel syndrome (opioid-induced gastrointestinal hyperalgesia), which has Rome IV criteria. These include abdominal pain that worsens with escalating doses and a “soar and crash” pattern.
A practical diagnostic pathway
Settles with a small dose increase or slower taper
Original pain returns at the original site; responds to a higher dose
Trial of dose reduction, rotation or an adjunct; improvement supports the diagnosis
How common is it?
Prevalence is not well defined. True incidence is unknown in every setting because there is no specific diagnostic test and study definitions are inconsistent; many studies equate high pain scores or opioid use with OIH without demonstrating altered sensory processing.5 The two main settings provide different kinds of evidence, and neither has an established higher prevalence.
| Perioperative (acute) OIH | Chronic opioid therapy | |
|---|---|---|
| Strength of evidence | Stronger causal (RCT) evidence: high-dose remifentanil reliably increases postoperative pain and opioid use5 | More consistent evidence of measurable hyperalgesia on sensory testing, but mostly observational and confounded5,13 |
| Key data | About 1,500 patients across 27 studies: higher intraoperative opioid doses (mostly remifentanil) linked to higher pain scores and 24 h morphine use; PAIN OUT registry data similar5 | Meta-analysis of 26 studies (2,706 participants): OIH on thermal pain tolerance testing but not on detection thresholds; lower pain tolerance after more than a month on opioids13,19 |
| Highest-risk groups | Younger patients; high-dose remifentanil, also linked to chronic postsurgical pain5,12 | Clearest in opioid use disorder and methadone/buprenorphine maintenance; about 45% of people on maintenance report chronic pain13,20 |
| Important co-factor or caveat | Surgery itself seems to be a co-factor: remifentanil causes no clinically significant hyperalgesia in healthy volunteers, and in animals only with an incision. Many trials used surrogate outcomes that cannot separate OIH from inadequate analgesia or acute tolerance5,12,17 | In chronic pain, clinically diagnosed OIH is mostly described in case reports at very high doses (median 850 mg oral morphine equivalent per day). Higher pain sensitivity may precede opioid use rather than result from it4,5 |
The settings overlap. Patients on long-term opioids who come for surgery probably already have abnormal pain processing, so prioritise non-opioid perioperative analgesia in this group.5 In chronic therapy, the dose escalation that tolerance prompts can itself drive OIH, which then leads to further escalation.11
Risk factors
| Domain | Risk factors |
|---|---|
| Drug and regimen | High doses; rapid escalation; remifentanil (above 0.2 μg/kg/min) and, to a lesser extent, fentanyl. Their fast on/off kinetics may be the reason. Abrupt cessation of remifentanil at 0.3 μg/kg/min or more2,5,18 |
| Patient | Younger age; opioid use disorder or methadone maintenance; low mood. Males showed more hyperalgesia with fentanyl in one study5,13 |
| Context | Surgical tissue injury appears to be a key co-factor for clinically relevant perioperative OIH12 |
Can OIH be prevented?
To some degree, yes. No guideline is dedicated to OIH prevention, and most evidence comes from small, heterogeneous perioperative RCTs.12 The core approach is opioid-sparing: the lowest effective dose, multimodal non-opioid analgesia, and avoidance of high-dose short-acting opioid infusions, remifentanil in particular. Adjuncts that target the underlying mechanisms add further protection.5,14,15
Perioperative prevention
- Remifentanil dosing: rates above 0.2 μg/kg/min increase OIH risk, and above 0.25 μg/kg/min acute tolerance becomes a problem. Tapering gradually at the end of surgery, rather than stopping abruptly, may reduce OIH, possibly through less withdrawal-induced spinal long-term potentiation.5
- Anaesthetic technique: propofol TIVA may carry a lower OIH risk than volatile anaesthesia, and adding nitrous oxide may reduce hyperalgesia.5
- Regional anaesthesia: nerve blocks or epidural analgesia reduce the overall opioid requirement.5
- Multimodal analgesia: combining at least two non-opioid approaches has the largest effect on opioid consumption and opioid adverse effects.5
Pharmacological adjuncts
| Agent | Rationale and evidence | Caveats |
|---|---|---|
| Ketamine | NMDA blockade; opioid-sparing; may reduce persistent postsurgical pain (Cochrane, small trials)5,14 | Psychotomimetic effects at higher doses; not enough on its own |
| Dexmedetomidine | The only agent better than placebo on all outcomes in a network meta-analysis (33 RCTs, 1,711 patients); lowest PONV15 | Sedation, bradycardia, hypotension |
| Amantadine | Ranked most effective for 24 h pain intensity in the same network meta-analysis12,15 | Ranking limited by heterogeneity between trials |
| Magnesium sulphate | NMDA blockade; reduced pain compared with placebo5,15 | Not enough on its own |
| Memantine | Oral NMDA antagonist; an RCT reported improvement in OIH symptoms8 | Single trial; role still to be defined |
| Pregabalin / gabapentin | α2δ-1 calcium channel blockade; pregabalin reduced pain5,14,15 | Sedation; respiratory depression when combined with opioids; optimal dose and timing unclear |
| NSAIDs / COX-2 inhibitors | Parecoxib, ibuprofen and flurbiprofen reduced pain compared with placebo5,15 | Renal and GI risk |
| IV lidocaine, steroids, paracetamol | Part of multimodal opioid-sparing analgesia5 | Limited evidence that they prevent OIH specifically |
Ketamine and dexmedetomidine regimens for prevention
| Agent / setting | Regimen | Evidence |
|---|---|---|
| Ketamine: ICU / postsurgical (SCCM) | 0.5 mg/kg IV, then 1–2 μg/kg/min (about 0.06–0.12 mg/kg/h) | Conditional recommendation, very low-quality evidence; reduces opioid use but not pain scores21 |
| Ketamine: intraoperative (ROCKet trial) | 0.5 mg/kg after induction (capped at 100 kg body weight), then 0.125 mg/kg/h to wound closure; may continue up to 72 h postoperatively (range 0.0625–0.25 mg/kg/h) | Dose chosen as within the range shown to inhibit OIH; trial testing prevention of chronic postsurgical pain23 |
| Dexmedetomidine: bolus | 0.5 μg/kg IV before or during remifentanil anaesthesia | Thyroidectomy RCT: hyperalgesia at 30 min 13% vs 48% with placebo; 0.2 μg/kg was not effective. Also effective in laparoscopic gynaecological surgery22,27 |
| Dexmedetomidine: infusion | 0.2–0.7 μg/kg/h | Meta-analysis of 13 RCTs (803 patients): longer time to first rescue analgesia (+46 min), less opioid use and lower 24 h pain, but more bradycardia24 |
These regimens assume adult, non-pregnant patients with normal haemodynamics and continuous monitoring during infusions. Neither drug is licensed for OIH.
- Opioid-tolerant surgical patients: an opioid-free regimen is often unrealistic. Ketamine is one of the few adjuncts studied in this group; in opioid-dependent patients undergoing lumbar fusion it reduced opioid consumption, and ASER/POQI consensus supports its use.5,28
- Combination: dexmedetomidine 0.25 μg/kg with nalmefene 0.1 μg/kg caused less bradycardia than dexmedetomidine 0.5 μg/kg alone, with faster recovery.27
- Non-drug preventive strategies: exercise and electroacupuncture have been studied, but almost entirely in preclinical models.12
Managing established OIH
In published cases, success rates were broadly similar across the three main strategies, and improvement came within a mean of about 8 days (range 1–28). Adjuvants allowed the largest dose reductions.4
Chronic opioid therapy: options
- Avoid rapid dose escalation. When pain worsens despite higher doses and no other explanation is found, suspect OIH rather than tolerance.16
- Reduce the dose gradually.16
- Rotate the opioid. Lipophilic agents such as methadone, fentanyl and buprenorphine may cause less tolerance or OIH than morphine, although rotation choices rest on limited data.4,11
- Switch to buprenorphine and/or add an NSAID.16
- Use non-drug therapies: CBT and physiotherapy.16
- Low-dose ketamine bursts, with or without low-dose midazolam, may reverse a poor opioid response and make rotation easier.11
Ketamine for established OIH and tapering
NMDA blockade is thought to reverse central sensitisation.14,29 Because NMDA overactivity underlies both tolerance and OIH, ketamine probably blunts both, and the clearest data come from inpatient low-dose infusions used to start a taper in long-term opioid users.14,35
Toulouse cohort: ketamine-assisted tapering33
59 patients with chronic non-cancer pain and opioid use disorder, all after failed outpatient tapers, were admitted for 5 days on a low-dose ketamine infusion.
- Daily MME fell from 207 mg to 92 mg at discharge and was 103 mg at 12 months.
- 68% achieved more than 50% reduction, and 12% stopped opioids entirely.
- No significant withdrawal occurred. However, the study was retrospective with no control group, and 17 patients were lost to follow-up.
- Dosing: analgesic infusions of about 0.1–0.2 mg/kg/h carry fewer adverse effects than sedative doses of 1–2 mg/kg/h.2
- Opioid-tolerant surgical patients: ASRA/AAPM/ASA consensus says ketamine “may be considered”. RCT results conflict: lower opioid use after spine surgery in one trial, negative results in others.36,37
- Caution: these cohorts enrolled long-term high-dose users without confirming OIH by testing, so results probably apply to tolerance as well, but do not prove it.33
Dexmedetomidine as a bridge during opioid reduction
Dexmedetomidine adds opioid-synergistic analgesia at the spinal level and suppresses withdrawal symptoms while the opioid dose comes down.14,31 Evidence for treatment of established OIH is limited to case series, mostly from ICU and palliative care.25,31,32
- The “70% reduction” figure is a total, not a starting cut. In the Belgrade and Hall series (11 inpatients), opioid reduction began when dexmedetomidine 0.2–0.7 μg/kg/h was started and continued over 2–7 days. Doses ended up about 70% lower on average with equal or better analgesia, but only 7 of 11 patients had substantial reductions by discharge.25,32
- Palliative series (Hofherr): in one patient with OIH, methadone was cut by 50% only after pain and anxiety improved on dexmedetomidine 0.2 μg/kg/h; the infusion was weaned after 48 h because of somnolence. Across 8 patients, none developed withdrawal despite significant opioid reductions.31
- Palliative RCTs: opioid doses and rescue use fell after dexmedetomidine was started, but there was no difference in pain control compared with control.34
A practical approach drawn from these reports
Withdrawal or persistent OIH during a taper?
Withdrawal can itself cause diffuse pain that looks like persistent OIH. Taper gradually, assess with the Clinical Opiate Withdrawal Scale (COWS), and slow the reduction if needed.5
| Feature | Withdrawal | Persistent OIH |
|---|---|---|
| Timing | Follows each dose step and eases over the following days | Present before the taper; does not track individual dose steps |
| Accompanying signs | Autonomic and GI symptoms: sweating, yawning, rhinorrhoea, diarrhoea, raised COWS score | Diffuse pain and allodynia without autonomic features |
| Effect of a small dose increase | Relieves symptoms | No improvement, or worse |
Key safety issues
- Ketamine: psychotomimetic effects increase with dose but are minimal at sub-anaesthetic doses; respiratory depression is minimal. Avoid, or use with caution, in psychosis, uncontrolled hypertension and raised intracranial pressure.14
- Dexmedetomidine: bradycardia and hypotension are the main limiting effects, so monitor continuously. It is licensed for sedation only, and multi-day courses for OIH are off-label; most published use was in ICU or palliative care units. Withdrawal from dexmedetomidine itself has been reported after prolonged infusions.24,26,38
- Evidence limits: there are no controlled trials of either drug specifically for tapering, no validated taper schedule, and the mechanism of benefit is unproven.25
“Reducing opioids in someone with OIH sounds counter-intuitive to patients, so the conversation matters as much as the plan. A slow, well-supported taper, combined with the right non-opioid treatments, often leaves people with less pain, not more.”
— Dr Murli Krishna, Consultant in Pain Medicine, Pain Spa
For patients: a plain-English explanation
What is it? Opioids such as morphine, oxycodone and fentanyl are strong painkillers. In some people, taking them, especially at high doses or for a long time, makes the nervous system more sensitive to pain. This is called opioid-induced hyperalgesia.
What might you notice? Pain that spreads to new areas, feels different from your original pain, or makes light touch uncomfortable. Increasing the dose may make it worse rather than better.
Is it the same as getting used to the medicine? No. “Tolerance” means the same dose works less well. Hyperalgesia means the medicine itself is turning up the volume on pain signals. The two can look similar, which is why a specialist assessment helps.
Can it be treated? Yes. Treatment often involves carefully lowering or changing the opioid, sometimes with the help of other medicines and non-drug treatments. Many people find their pain improves within days to weeks.
Important: please do not stop or reduce your opioids suddenly on your own. Stopping too quickly can cause withdrawal and more pain. Talk to your doctor or pain specialist first.
How Pain Spa can help
Dr Murli Krishna FFPMRCA
Consultant in Pain Medicine, Pain Spa
Dr Krishna assesses patients whose pain has become harder to control despite increasing opioid doses, and works with them and their GP to separate tolerance, hyperalgesia, withdrawal and changes in the underlying condition.
Pain Spa offers specialist medication review, structured and supported opioid reduction, and non-opioid options including image-guided injections across a wide range of pain conditions, helping patients reduce reliance on opioids while keeping pain under control.
Concerned about opioids and worsening pain? Contact Pain Spa to arrange a consultation.
Glossary
| Allodynia | Pain from a stimulus that is not normally painful, such as light touch |
| Hyperalgesia | An exaggerated pain response to a stimulus that is normally painful |
| Tolerance | Reduced effect from the same opioid dose over time |
| Central sensitisation | Amplification of pain signalling within the spinal cord and brain |
| NMDA receptor | Glutamate receptor central to spinal sensitisation; the target of ketamine, magnesium, memantine and amantadine |
| OME / MME | Oral morphine equivalent / morphine milligram equivalent: total daily opioid dose expressed as oral morphine |
| QST | Quantitative sensory testing: standardised measurement of responses to heat, cold, pressure and touch |
| TIVA | Total intravenous anaesthesia, usually with propofol |
| COWS | Clinical Opiate Withdrawal Scale |
| Narcotic bowel syndrome | Opioid-induced gastrointestinal hyperalgesia: abdominal pain that worsens with continued or escalating opioid use |
References
- Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations. CNS Drugs 2015.
- Moran BL, Myburgh JA, Scott DA. The complications of opioid use during and post-intensive care admission: a narrative review. Anaesth Intensive Care 2022.
- Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet 2011.
- Guichard L, Hirve A, Demiri M, Martinez V. Opioid-induced hyperalgesia in patients with chronic pain: a systematic review of published cases. Clin J Pain 2021.
- Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia – when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet 2019.
- Jin D, Chen H, Huang Y, Chen SR, Pan HL. Sensory neuron BRAF mediates opioid-induced hyperalgesia and tolerance via presynaptic NMDA receptor hyperactivity. J Clin Invest 2026.
- Chen SR, Chen H, Jin D, Pan HL. Brief opioid exposure paradoxically augments primary afferent input to spinal excitatory neurons via α2δ-1-dependent presynaptic NMDA receptors. J Neurosci 2022.
- Anjomshoaa A, Zolghadriha A, Haj-Seyed-Taghia NS, Saed O, Faghihzadeh E. Memantine treatment improves opioid-induced hyperalgesia symptoms: randomised clinical trial. Sci Rep 2025.
- Araldi D, Bogen O, Green PG, Levine JD. Role of nociceptor toll-like receptor 4 (TLR4) in opioid-induced hyperalgesia and hyperalgesic priming. J Neurosci 2019.
- Liu X, Bae C, Liu B, et al. Development of opioid-induced hyperalgesia depends on reactive astrocytes controlled by Wnt5a signaling. Mol Psychiatry 2023.
- Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs 2019.
- Koponen ME, Naray E, Hales TG, Forget P. Pharmacological interventions for remifentanil-induced hyperalgesia: a systematic review and network meta-analysis of preclinical trials. PLoS One 2023.
- Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth 2019.
- Martyn JAJ, Mao J, Bittner EA. Opioid tolerance in critical illness. N Engl J Med 2019.
- Xie WJ, Hong JS, Feng CF, et al. Pharmacological interventions for preventing opioid-induced hyperalgesia in adults after opioid-based anesthesia: a systematic review and network meta-analysis. Front Pharmacol 2023.
- Sonoda K, Wakabayashi M. Long-term opioid therapy for nonterminal pain. Am Fam Physician 2025.
- Jin Y, Mao Y, Chen D, et al. Thalamocortical circuits drive remifentanil-induced postoperative hyperalgesia. J Clin Invest 2022.
- Vitin AA, Egan TD. Remifentanil-induced hyperalgesia: the current state of affairs. Curr Opin Anaesthesiol 2024.
- Montgomery LS. Pain management with opioids in adults. J Neurosci Res 2022.
- Trøstheim M, Eikemo M. Hyperalgesia in patients with a history of opioid use disorder: a systematic review and meta-analysis. JAMA Psychiatry 2024.
- Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med 2018.
- Wu Z, Yu J, Lin Q, et al. Effects of an intraoperative intravenous bolus dose of dexmedetomidine on remifentanil-induced postinfusion hyperalgesia in patients undergoing thyroidectomy: a double-blind randomized controlled trial. Anesth Analg 2021.
- Peyton PJ, Braat S, De Silva A, et al. Rationale and design of a large trial of perioperative ketamine for prevention of chronic post-surgical pain. Trials 2024.
- Singh NP, Siddiqui NT, Khan J, et al. Intravenous dexmedetomidine and its effects on remifentanil-induced hyperalgesia and opioid consumption: a systematic review and meta-analysis of randomized controlled trials. J Clin Anesth 2026.
- Malotte K, Walker K, Rosielle DA. Dexmedetomidine #280. J Palliat Med 2014.
- Dexmedetomidine. FDA drug label. Updated 2 June 2026.
- Jia Z, Chen Y, Gao T, et al. Nalmefene vs. dexmedetomidine for prevention of postoperative hyperalgesia in patients undergoing laparoscopic gynecological surgery with remifentanil infusion: a randomized double-blind controlled trial. Front Pharmacol 2023.
- Edwards DA, Hedrick TL, Jayaram J, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative joint consensus statement on perioperative management of patients on preoperative opioid therapy. Anesth Analg 2019.
- Phan JH, Smith MA. Low-dose oral ketamine for pain management: a primer for clinicians. Ann Pharmacother 2026.
- Kaye AD, Wolf MC, Dufour SI, et al. Efficacy of ketamine infusion for treatment of opioid use disorder in patients with chronic pain: a narrative review. Curr Pain Headache Rep 2025.
- Hofherr ML, Abrahm JL, Rickerson E. Dexmedetomidine: a novel strategy for patients with intractable pain, opioid-induced hyperalgesia, or delirium at the end of life. J Palliat Med 2020.
- Belgrade M, Hall S. Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med 2010.
- Elyn A, Roussin A, Lestrade C, et al. Low-dose ketamine infusion to facilitate opioid tapering in chronic non-cancer pain with opioid-use disorder: a historical cohort study. Reg Anesth Pain Med 2025.
- Tavares T, Almeida J, Gonçalves E, Abelha F. Dexmedetomidine in palliative care: a versatile new weapon against delirium and pain – systematic review. J Palliat Med 2024.
- Chou CZ, Hopkins TJ, Badiola I, et al. Top ten tips palliative care clinicians should know about interventional pain and procedures. J Palliat Med 2020.
- Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from ASRA, AAPM and ASA. Reg Anesth Pain Med 2018.
- Kummer I, Lüthi A, Klingler G, et al. Adjuvant analgesics in acute pain – evaluation of efficacy. Curr Pain Headache Rep 2024.
- Mason M, Mesarwi P, Le M, et al. Utilizing dexmedetomidine for opioid-resistant pain and anxiety in the palliative care unit: a case report on efficacy, withdrawal challenges, and protocol adaptations. J Palliat Med 2025.
This article is intended for healthcare professionals and is for educational purposes only. It does not replace individual clinical assessment. Drug doses quoted are from published studies and may be off-label; check local formularies and product information before prescribing. Patients should not change their medication without medical advice.